NOCIL Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Volume recovery takes hold, realizations lag: Second-half volumes surged 12% YoY, pushing Q4 to an index of 150, but realizations remain under pressure from lower-priced imports and an FTA-driven loss of basic duty protection on one product.
• Margins hit a trough on legacy costs and utility spikes: EBITDA margin fell to 6.4% in Q4 and 7.7% for the full year, weighed down by legacy high-cost inventory, higher gas costs, maintenance shutdowns, and a narrowing of spreads from FTA imports.
• Antidumping relief is progressing, not yet priced in: DGTR recommended positive final findings for TDQ and Sulphenamides in March 2026, with central government approval expected around mid-June; findings for Pilflex 13 and 4ADPA are due in the coming months.
• Price hikes and cost actions are set up for FY27: The company raised prices for non-contractual business late in Q4 and for contractual business from the current quarter, while internal cost optimization delivered a ₹18-20 crore reduction in other expenditure.
• What to watch next quarter: Whether the price hikes stick and flow through to realizations, the timing and quantum of any antidumping duty imposed, and whether Q4 volumes truly form the new base as management expects.

Volume & Demand Environment

• A tale of two halves: FY26 volumes contracted 5% YoY in the first half, then rebounded to 12% YoY growth in the second half as GST 2.0 drove demand, yielding 3% full-year volume growth.
• Q4 volumes hit a multi-year high: The volume index reached 150 (base Q1 FY20 = 100), a level seen only once before in the last 10-12 quarters, and management confirmed this can become the base going forward.
• Export markets stable, USA recovering: Europe and Asia volumes were stable despite ongoing freight and transit disruptions; USA volumes, which had been hit ~50% by higher duties, are now moving up positively as supply chains adjust.
• Latex volumes face Chinese competition: Latex volumes have stabilized after earlier tariff disruptions, but increased competitive intensity from Chinese players is a headwind; management expects stability in FY27 barring significant disruption.
• Import spike in Jan-Feb raises questions: Antioxidant imports picked up significantly YoY, potentially via Thailand and Korea FTA routes, and partly due to year-end advanced license usage; management has not observed widespread pre-antidumping stockpiling by customers.
• Global rubber consumption growth has structurally slowed: Growth halved from ~5.7% CAGR (2013-18) to ~2.8% CAGR (2022-25), per an analyst's math; management sees 2-2.5% as realistic, driven by stronger Asian growth and continual global disruptions.

V.S. Anand: "Yes, yes. We can." (confirming Q4 volumes can become the base)

Realizations, Margins & Cost Actions

• Realizations under sustained pressure: Lower-priced imports continued to weigh on realizations throughout the quarter and the full year.
• FTA regime erased basic duty protection: One product imported under an FTA regime lost its basic duty protection, significantly narrowing spreads and impacting profitability; management views this as a correction that has now normalized.
• Q4 margin compressed by multiple one-offs: EBITDA margin fell to 6.4%, hit by moderately higher gas costs, maintenance shutdown activities, and an inventory depletion effect reflected in the stock change debit; had production not been cut due to energy prices in March, EBITDA would have been higher.
• Full-year margin dragged by legacy inventory: FY26 EBITDA margin of 7.7% was impacted by legacy high-cost inventories spilling into the first half, plus the FTA-driven spread narrowing.
• Price hikes timed late in Q4: Price increases for non-contractual positions were taken only in the second half of March, so very few days benefited Q4; the impact will be seen in the upcoming quarter, and contractual business prices were revised upward from the present quarter.
• Cost optimization delivered tangible savings: Utility cost reduction efforts saved ₹10-11 crores; maintenance expenses were also reduced; administrative cost optimization through task forces; overall other expenditure fell ₹18-20 crores.
• Conversion cost expected to fall further: Management expects absolute conversion cost per kg to go down further, though no specific number was given.
• Working capital improvement funded capex: Better working capital management, largely in inventory, released cash that financed capital expenditure.

P. Srinivasan: "The larger challenge which has been for us in this the spread got narrowed down because one of our products was imported largely from FTA regime, where the protection which was there earlier in the form of basic duty got wiped out. And that impacted the bigger on the profitability."

Antidumping & Trade Remedies

• DGTR recommended positive findings for two product groups: In March 2026, the Director General of Trade Remedies recommended positive final findings for antioxidant TDQ and Sulphenamides (CBS and NS), subject to central government approvals.
• Central government decision expected mid-June: Approval typically takes about 90 days, putting the timeline around the middle of June 2026.
• Two more findings due soon: DGTR findings for Pilflex 13 are expected in the next month or so; findings for 4ADPA are expected in a few months.
• Duty quantum remains unknown: Management declined to speculate on the quantum of duty the finance ministry might approve, calling it premature.
• Peak spread potential also unquantified: When asked what peak spreads could look like under antidumping duty over a 5-6 year horizon, management again declined to comment, calling it premature.
• FTA compliance being flagged: NOCIL is highlighting to authorities the need to ensure value addition is within FTA norms; the matter has been taken up but no specific outcome yet.

Capex & Capacity Expansion

• TDQ capex at Dahej completed: The project announced in March 2024 is finished; trial production has commenced and samples will be sent for customer approval.
• New ₹130 crores capex announced: A comprehensive integrated facility in the specialty portion of rubber chemicals was announced on 16 March 2026, with completion expected by H1 FY28.
• Customer approvals will pace the ramp: Non-tire-based business from the expanded plant is expected to start much earlier; tire-based customers will take longer, with real traction from larger customers expected in 6-8 months.
• Specialty mix target raised: Management expects the specialty mix to reach 20% post-commissioning of the new capex and at peak utilization levels, up from the current ~15% spread over the industry average.
• No debt drawn yet for capex: The company has not borrowed so far and will utilize bank lines when needed.

Product & Market Developments

• 6PPD alternative in advanced development: NOCIL is working on an alternative to 6PPD, the largest and most reliable rubber antioxidant, due to aqua toxicity concerns first raised in California; dedicated teams are on it, but the alternative is still some time away and in trial/testing stages.
• New products expected to gain traction in FY27: Management expects higher volumes and traction on new products, initially in pickup mode without significant impact on overall volumes, but gradually building towards year-end.
• Volume strategy prioritizes absolute EBITDA over margin rate: Management is willing to accept a lower specific margin to gain additional volumes, aiming to increase the absolute overall number with available capacity.
• Customer stickiness rests on reliability, not just price: While price is critical, NOCIL emphasizes proving its capability to supply reliably in quality and during difficult times as a differentiator.
• Chinese competitor's India capex not seen as a major threat: Management does not view a Chinese competitor's announced Indian capacity expansion as having a major impact.

V. S. Anand: "This has been a finding which started in California. And so there is a discussion in terms of the aqua toxicity of this largely used product, which is the largest rubber chemical used, the most reliable rubber chemical from a safety point of view. So there are discussions and all players are looking to find an alternative, including us, and we are working on it."

Guidance & Commitments

Key Metrics